Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy has successfully issued and registered a total of 30,709,056 new shares, significantly altering the company’s share structure by increasing the total registered shares to 104,624,864. This move is part of a broader strategy to bolster their immunotherapy platform, with the new shares expected to commence trading on Nasdaq First North and AIM around 24 June 2024. The influx of new shares, which now represent approximately 31.2% of Faron’s post-offering equity, is aimed at advancing the company’s leading asset, bexmarilimab, in the fight against hematological cancers.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
